Ascent Therapeutics
Ascent Therapeutics is now Anchor Therapeutics!
About Ascent Therapeutics
Ascent Therapeutics, a biopharmaceutical firm, was established to capitalize on a novel drug development platform originating from scientific research conducted in the late 1990s. The company's scientific underpinnings were laid by co-founders Athan Kuliopulos and Lidija Covic, scientists at Tufts Medical Center who pioneered the core technology. Their work led to patent filings in 2000 and 2001, setting the stage for the company's formation. Ascent Therapeutics secured its Series A financing in October 2007, which included investments from Novartis Option Fund, Healthcare Ventures, and TVM Capital, and officially launched in 2008 after a period of operating in stealth mode. Michael Webb is also recognized as a founder, and the management team was strengthened with the appointment of Frederick Jones, M.D., as President and CEO in August 2008.
The company's business was centered on the discovery and development of Pepducin® lipopeptides, a new class of molecules designed to modulate G protein-coupled receptors (GPCRs). This technology represented a distinct approach to drug development by targeting the intracellular domains of GPCRs, which are implicated in a wide array of serious diseases, including inflammation, cancer, and cardiovascular disease. The business model focused on leveraging this proprietary platform to build an internal pipeline of therapeutic products and to form strategic partnerships with other pharmaceutical companies. A significant milestone was a licensing option agreement with the Novartis Option Fund, valued at over $200 million in potential fees and milestones, to discover and develop Pepducin drug candidates against a specific GPCR target.
The core service of Ascent Therapeutics was its Pepducin technology platform. These molecules are short peptides linked to a lipid moiety, which allows them to anchor in the cell membrane and interact with the internal portions of GPCRs. This mechanism provided a way to modulate GPCR signaling from inside the cell, offering the potential to target receptors that had been difficult to address with traditional small molecules and biologics that typically target the exterior of the cell. By offering a way to either inhibit or activate GPCR signals, the platform aimed to greatly expand the range of druggable targets within this well-validated family of receptors. In March 2010, the company rebranded to Anchor Therapeutics to more accurately reflect its core technology. The company was subsequently acquired in August 2016.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Cambridge, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 52.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2007 | $19M | $76M | HealthCare Ventures · Novartis Venture Fund · TVM Capital Life Science | — |
| SPINOUT✓Other financing | Jan 2006 | $0 | — | Tufts University | — |
Growth signals
Latest recorded traffic for Ascent Therapeutics is 0 monthly website visits. Ascent Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ascent Therapeutics in the Cambridge ecosystem
The Ascent Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- HVHealthCare Ventures
Novartis Venture Fund
TVM Capital Life Science
Other known investors1 additional known investor
Tufts University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ascent Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ascent Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









